Hong Kong Prostate Cancer Study Group Database
About this study
Prostate cancer (PCa) is ranked 3rd in annual incidence of male cancer and ranked 5th for cancer-related death in men in Hong Kong which accounts for about 9.1 deaths per 100,000 men in 2011. Its incidence is rising rapidly, almost tripled in the past 10 years. In Hong Kong, the two main screening methods for PCa are digital rectal examination (DRE) and serum prostate-specific antigen (PSA) level blood test, and the gold standard of diagnosis of PCa is transrectal ultrasound (TRUS) with prostate biopsy. For those who diagnosed with PCa, there are different kinds of managements depending on patient's age group and disease stage. Watchful waiting is for older patients who presents with low-risk prostate cancer. And active surveillance is applicable to patients who are eligible for potentially curative management. While radiotherapy or radical prostatectomy are recommended as curative management for early stage PCa, androgen deprivation therapy (ADT) is the main treatment modality for advanced or recurrent prostate cancer. Advanced prostate cancer that recurrence is called castration refractory prostate cancer (CRPC). There are many new agents, including second line hormonal therapy, chemotherapy, androgen biosynthesis inhibitors, immunotherapy, bone targeting agents etc., available for the further management. In this study, investigators would like to establish a local prostate cancer registry to facilitate the collection of clinical information and outcomes of prostate cancer management. Hopefully, this registry can provide information regarding the epidemiology, natural history, and treatment outcomes of local prostate cancer. The information would be helpful for research, public education, health care planning and also international collaboration. Ultimately, patients and public would be benefited from these works.
- Condition
- Prostate Cancer
- Tested
- No intervention
- Sponsor
- Chinese University of Hong Kong
Who can join
- Age
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
Inclusion 5
- Minimum age: 18 years
- Eligible sex: Male
- Study condition: Prostate Cancer
- Patient at the age of 18 or above
- Patients with clinical diagnosis of prostate cancer
Exclusion 1
- Patients diagnosed to have ductal type of prostate cancer
Where
1 site, 1 recruiting
Prince of Wales Hospital
Shatin, Hong Kong
Contact
-
Chi Fai NG, MD
3505 2625 ngcf@surgery.cuhk.edu.hk
Potential match only. Final eligibility is determined by the study team.